IDEAYA Biosciences Inc at Morgan Stanley Global Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Judah Frommer - Morgan Stanley & Co. LLC - Analyst : <_ALACRA_META_ABSTRACT>So with that Yujiro, maybe we could start with a quick overview of the company for those that are less familiar with IDEAYA.

Question: Judah Frommer - Morgan Stanley & Co. LLC - Analyst : That's a great overview. We're going to have try to impact as much as possible in the time allotted. (Conference Instructions) So starting with Darovasertib, you had an impressive data updated ASCO in neoadjuvant uveal melanoma from your IST and separately with a company-sponsored Phase 2 study, can you provide a recap of the data and what's deemed clinically relevant in this setting?

Question: Judah Frommer - Morgan Stanley & Co. LLC - Analyst : Okay, great. So we are expecting a second half update from the company sponsor neoadjuvant study, how many more patients and how much more follow-up can investors expect versus the June update?

Question: Judah Frommer - Morgan Stanley & Co. LLC - Analyst : Okay, great. And you recently noted as part of your earnings that you have scheduled a Type C meeting with FDA for Q3. Can you remind us of what you hope to gain alignment with FDA on as part of the meeting? And how will you provide the update on the feedback? Could this update come with the Phase 2 company sponsored data update? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. SEPTEMBER 04, 2024 / 9:35PM, IDYA.OQ - IDEAYA Biosciences Inc at Morgan Stanley Global Healthcare Conference

Question: Judah Frommer - Morgan Stanley & Co. LLC - Analyst : Okay. No, that's great color. So if we move on to the Phase 2/3 registrational study you're running in frontline metastatic UM. Can you elaborate on the study design and next updates for this study?

Question: Judah Frommer - Morgan Stanley & Co. LLC - Analyst : Got it. And if we move on to the adjuvant uveal melanoma setting, that's another large market. Do you have plans for that setting?

Question: Judah Frommer - Morgan Stanley & Co. LLC - Analyst : Okay. That makes sense. And you touched on pieces of this in your answers. But just to wrap up the Daro section, can you discuss the unmet need that remains in uveal melanoma and the market opportunity for Daro in general.

Question: Judah Frommer - Morgan Stanley & Co. LLC - Analyst : That makes sense. Okay. So moving on to IDE397, your MAT2A inhibitor. You recently showed impressive monotherapy data in bladder and non-small cell lung cancer. How are you thinking about a monotherapy strategy given you have combination studies with AMG 193 and Trodelvy? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. SEPTEMBER 04, 2024 / 9:35PM, IDYA.OQ - IDEAYA Biosciences Inc at Morgan Stanley Global Healthcare Conference

Question: Judah Frommer - Morgan Stanley & Co. LLC - Analyst : Okay, got it. Maybe just a couple of more pointed questions on the combos. So if we start with PRMT5, can you just walk us through briefly the mechanistic rationale for pairing of MAT2A inhibitor with the PRMT5 inhibitor and just again, remind us what the next updates are for that combo.

Question: Judah Frommer - Morgan Stanley & Co. LLC - Analyst : Okay. Got it. And similar question for the combination with Trodelvy in urothelial cancer. If you could walk us through the mechanistic rationale and again, the updates for that combo we should expect?

Question: Judah Frommer - Morgan Stanley & Co. LLC - Analyst : Got it. Okay. And just to wrap up here, maybe a little bit more on the market opportunity for IDE397 in these priority tumor types you highlighted. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. SEPTEMBER 04, 2024 / 9:35PM, IDYA.OQ - IDEAYA Biosciences Inc at Morgan Stanley Global Healthcare Conference

Question: Judah Frommer - Morgan Stanley & Co. LLC - Analyst : Okay, great. Moving on to PARG. So if we think about IDE161, can you discuss the potential for this target and how it differs from PARP inhibition?

Question: Judah Frommer - Morgan Stanley & Co. LLC - Analyst : Okay, got it. And you sort of touched on this, but maybe just a little more expansion on your clinical strategy in both the mono and combo therapies, including, like you mentioned with KEYTRUDA? And what would be the next updates that we should comment on here? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. SEPTEMBER 04, 2024 / 9:35PM, IDYA.OQ - IDEAYA Biosciences Inc at Morgan Stanley Global Healthcare Conference

Question: Judah Frommer - Morgan Stanley & Co. LLC - Analyst : Got it. Got it. Okay. So with the remaining time, I figured we could tried to pepper you with some questions on your preclinical program. So maybe we start with the Werner program, that's in collaboration with GSK. Can you expand on the history around this target and what makes you excited about it? What are next steps for the IND here?

Question: Judah Frommer - Morgan Stanley & Co. LLC - Analyst : Got it. Got it. Moving onto the Pol Theta program with GSK. Can you give us an update on where you are with that program?

Question: Judah Frommer - Morgan Stanley & Co. LLC - Analyst : Got it. Okay. And you recently announced an 1option and license agreement for a potential first in class B7H3/PTK7 bispecific ADC program with Biocytogen. So can you walk us through that program a little bit of the background and next step there?

Question: Judah Frommer - Morgan Stanley & Co. LLC - Analyst : Okay. It makes sense. So maybe we could wrap up with some guidance you provided that you're targeting two additional development candidate nominations in MTAP and the KAT6 pathway this year. Is there anything you'd want to highlight on either of those at this time?

Question: Judah Frommer - Morgan Stanley & Co. LLC - Analyst : Got it. Okay. I don't see any questions in the audience. So I think we can wrap up with that. But thank you very much. That was a great overview.